ARS Pharmaceuticals (SPRY) EBT Margin (2022 - 2026)
ARS Pharmaceuticals (SPRY) reported EBT Margin of 422.96% for Q1 2026, up 4532.0% on a YoY basis from 9.13% in Q1 2025, and down 172.06% sequentially from 155.46% in Q4 2025.
ARS Pharmaceuticals (SPRY) EBT Margin (2022 - 2026) Analysis & Trends
ARS Pharmaceuticals (SPRY) has 5 years of EBT Margin data on file, last reported at 422.96% in Q1 2026.
- For the quarter ending Q1 2026, EBT Margin rose 4532.0% year-over-year to 422.96%; the trailing twelve-month figure through Mar 2026 stood at 479.71% (down 26051.0% YoY), and the FY2025 full-year result was 203.35%, down 21264.0% from the prior year.
- EBT Margin fell to 422.96% in Q1 2026, from 155.46% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 54.59% in Q4 2024 to a low of 382009450.0% in Q2 2023.
- A 5-year average of 44544778.1% and a median of 1749.47% in 2022 frame the typical range for EBT Margin.
- Across the five-year window, EBT Margin sank 2000000000 bps in 2023 and soared 2000000000 bps in 2024, its largest moves.
- Tracing SPRY's EBT Margin over 5 years: stood at 8018.52% in 2022, then slumped by 4763990 bps to 382009450.0% in 2023, then jumped by 100 bps to 54.59% in 2024, then slumped by 385 bps to 155.46% in 2025, then plunged by 172 bps to 422.96% in 2026.
- Business Quant data shows SPRY's EBT Margin at 422.96% in Q1 2026, 155.46% in Q4 2025, and 347.61% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 17.13% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 33.74% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | ARS Pharmaceuticals | 595.78 Mn | 394.81 Mn | - | -422.96% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -422.96% |
| Dec 31, 2025 | -155.46% |
| Sep 30, 2025 | -347.61% |
| Jun 30, 2025 | -1,414.22% |
| Mar 31, 2025 | -468.28% |
| Dec 31, 2024 | 54.59% |
| Sep 30, 2024 | -7,514.89% |
| Jun 30, 2024 | -13,481.40% |
| Jun 30, 2023 | -382,009,450.00% |
| Mar 31, 2023 | -197,036,230.00% |
| Sep 30, 2022 | -8,018.52% |
| Jun 30, 2022 | -2,917.03% |
| Mar 31, 2022 | -1,749.47% |